| Item type |
デフォルトアイテムタイプ（フル）(1) |
| 公開日 |
2010-02-23 |
| タイトル |
|
|
タイトル |
［原著］A Prospective Trial of Oral Betamethason and Oral Lorazepam in the Management of Delayed Nausea and Vomiting Induced by Cisplatin-Based Chemotherapy |
|
言語 |
ja |
| 作成者 |
Uehara, Tadashi
Yohena, Tomofumi
Kanematsu, Takanori
Teruya, Takao
Ikeda, Jiro
Okamoto, Junichi
Asoh, Hiroshi
Ichinose, Yukito
|
| アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
| 権利情報 |
|
|
言語 |
ja |
|
権利情報 |
琉球医学会 |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Betamethason |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Chemotherapy |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Cisplatm |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Delayed emesis |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Lorazepam |
| 主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
Lung Cancer |
| 内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Purpose: The optimal treatment modality for delayed emesis occurring later than 24 hours after the administration of cisplatin-based chemotherapy has not yet been established. Patients and Methods: Twenty patients received 5-hydroxytryptamine 3 receptor antagonist intravenously for the treatment of acute emesis just before cisplatm infusion in the first cycle of treatment, and the thereafter they received oral administration of betamethason ($\2mgtimes3/day$) plus oral lorazepam ($\0.5mgtimes3/day$) for 5 days in trial I. In trial II, 14 patients who received the other anti-emetic regimen (methylprednisolone plus metoclopramide) for delayed emesis in the first cycle of chemotherapy were treated by this regimen for the second cycle of treatment. A complete response (CR) was defined as no emetic episodes and a partial response (PR) as no vomiting episodes but some nausea. The effects of anti-emetic treatments were evaluated for 5 days from the next day after cisplatin administration. Results: The mean control rate (percentage of CR+PR) and CR rate for delayed emesis for the 5-day period were 97% and 84%, respectively in trial I. The mean control rate in patients undergoing the other anti-emetic regimen in the first cycle of chemotherapy was 60% compared to 96% in the same patients undergoing this regimen in the second cycle of the same chemotherapy in trial II. Conclusions: Oral betamethason plus lorazepam demonstrated a high control rate for delayed nausea and vomiting induced by cisplatin-based chemotherapy. |
| 内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
論文 |
| 出版者 |
|
|
出版者 |
琉球医学会 |
|
言語 |
ja |
| 出版者 |
|
|
出版者 |
Ryukyu Medical Association |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1346-888X |
| 収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0289-1530 |
| 収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AN10369445 |
| 収録物名 |
|
|
収録物名 |
琉球医学会誌 = Ryukyu Medical Journal |
|
言語 |
ja |
| 書誌情報 |
巻 25,
号 1・2,
p. 17-22,
発行日 2006
|
v25p17.pdf
